Skip to Content

Join the 'Vemurafenib' group to help and get support from people like you.

Vemurafenib News

Zelboraf Approved for Rare Blood Cancer

Posted 7 Nov 2017 by Drugs.com

MONDAY, Nov. 6, 2017 – Zelboraf (vemurafenib) has been approved by the U.S. Food and Drug Administration as the first drug to treat Erdheim-Chester Disease, a rare but deadly blood cancer. The approval covers patients who have a genetic mutation called BRAF V600. Erdheim-Chester Disease is a slow-growing cancer that originates in bone marrow, causing a spike in a type of white blood cell called ...

FDA Approves Zelboraf (vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation

Posted 6 Nov 2017 by Drugs.com

November 6, 2017 - The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD. “Today’s app ...

Doctors' Group Offers Ideas for Easing Cancer Costs

Posted 19 Jul 2017 by Drugs.com

WEDNESDAY, July 19, 2017 – New cancer drugs routinely cost $100,000 a year or more, and older cancer drugs are rising in price, too. Now, the American Society of Clinical Oncology (ASCO) has some suggestions for easing patients' money woes. The proposals include allowing Medicare to negotiate drug prices, legalizing the importation of drugs, and adopting bundled, or group, payment programs. In ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

FDA Approves Cotellic (cobimetinib) for the Combination Treatment of Advanced Melanoma

Posted 10 Nov 2015 by Drugs.com

November 10, 2015 – The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation). Melanoma is the most aggressive and dangerous form of skin cancer in the United ...

Cotellic Approved for Advanced Melanoma

Posted 10 Nov 2015 by Drugs.com

TUESDAY, Nov. 10, 2015 – Cotellic (cobimetinib) in combination with another chemotherapy, vemurafenib (Zelboraf) has been approved by the U.S. Food and Drug Administration to treat melanoma skin cancer that has spread or cannot be surgically removed, the agency said Tuesday in a news release. Melanoma is the most aggressive and dangerous form of skin cancer. Nearly 74,000 Americans are projected ...

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations ...

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be ...

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the ...

New Melanoma Drug May Extend Survival

Posted 25 Jun 2012 by Drugs.com

MONDAY, June 25 – New research suggests that a new drug does a better job of combating advanced skin cancer in melanoma patients than chemotherapy. However, patients typically still got worse after only a few months on the drug. The drug, called dabrafenib, blocks a signaling protein and is used to treat melanomas with a specific genetic mutation. About half of melanoma patients have this ...

Two-Drug Combo May Be Safe for Melanoma Treatment

Posted 16 May 2012 by Drugs.com

WEDNESDAY, May 16 – A preliminary, first-stage study funded by a pharmaceutical company shows promising results for an experimental double-drug therapy for melanoma. The two drugs, known as dabrafenib and trametinib, appeared to delay progression of the potentially deadly skin cancer with fewer side effects than an existing drug called vemurafenib (Zelboraf). However, the research into the drug ...

Melanoma Drug's Link to Other Skin Cancers Identified

Posted 18 Jan 2012 by Drugs.com

WEDNESDAY, Jan. 18 – The recently approved drug vemurafenib (Zelboraf) has been hailed as a breakthrough in the treatment of melanoma, the deadliest form of skin cancer. But roughly one-quarter of patients who take the medication develop a troublesome side effect: secondary skin cancers called squamous cell carcinomas. Now, a new study by researchers at the Jonsson Comprehensive Cancer Center at ...

Targeted Drugs, Lung CT Screening Top Cancer Advances in 2011

Posted 6 Dec 2011 by Drugs.com

TUESDAY, Dec. 6 – As the war against cancer continues, a group representing U.S. oncologists has picked its "Top Five" list of advances in cancer care for 2011. Leading the list are approvals for a bevy of new, targeted drugs for tough-to-treat malignancies, plus promising results suggesting CT chest scans may be an early-detection screen for lung cancer. The American Society of Clinical ...

The War on Cancer Continues

Posted 20 Sep 2011 by Drugs.com

TUESDAY, Sept. 20 – Forty years after President Nixon signed the National Cancer Act into law and pledged to put the country's resources to work to find better treatments for cancer, substantial victories have been scored against some, but not all, cancers. That's the core finding of a new report, the AACR Cancer Progress Report 2011, released Tuesday by the American Association for Cancer ...

Ask a Question

Further Information

Related Condition Support Groups

Melanoma - Metastatic, Erdheim-Chester Disease

Related Drug Support Groups

Zelboraf

Vemurafenib Patient Information at Drugs.com